Yonhap Infomax NewsJan 16
D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.
#YonhapInfomax #DDPharmatech #DD01 #MASH #TechnologyTransfer #JPmorganHealthcareConference #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100288
D&D Pharmatech in Talks for Technology Transfer of MASH Therapy Candidate DD01

D&D Pharmatech Co. revealed at the JP Morgan Healthcare Conference that it is in technology transfer talks with global pharmaceutical firms for DD01, its MASH therapy candidate, and plans to announce topline Phase 2 results in May.

Yonhap Infomax
Yonhap Infomax NewsSep 22, 2025
D&D Pharmatech shares hit the daily upper limit after news that partner Metsera is in talks for a $7.3 billion acquisition by Pfizer, boosting market optimism.
#YonhapInfomax #DDPharmatech #Metsera #Pfizer #ObesityTreatment #MASHMarketGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82823
D&D Pharmatech Shares Surge to Daily Limit on Expectations of Partner Metsera’s Acquisition

D&D Pharmatech shares hit the daily upper limit after news that partner Metsera is in talks for a $7.3 billion acquisition by Pfizer, boosting market optimism.

Yonhap Infomax